Is Vaxart Inc (NASDAQ:VXRT) Stock a Good Investment Bet Right Now?

August 4, 2021

Investors may choose to avoid Vaxart (NASDAQ:VXRT) presently despite its interesting business model. Reasons such as the binary nature of biotech investing as well as time for commercialization are some of the factors that can be considered as concerns. Analysts view the stock as much of a gamble and Covid-19 exemplifies that risk. The company sells oral vaccines in tablet form and harnesses its VAAST platform for delivering two payloads…


Vaxart Inc (NASDAQ:VXRT) Stock Moves Toward $8 After The News: How Far Can it Go?

August 2, 2021

Clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, Vaxart (NASDAQ:VXRT) saw its shares surge by almost 10% after it announced FDA clearing investigational new Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. Andrei Floroiu, Vaxart’s CEO, said that along with S-only and S+N constructs comprise of its COVID-19 vaccine candidate portfolio. The clinical trial will enable the firm to compare…